https://biosherpa.com/home daily 1.0 2021-04-11 https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1618115402358-W5IM5Q6BQHOU7NE9QHU4/BioSherpaLLC-Banner.png Home https://biosherpa.com/the-biosherpa-sts-solution daily 0.75 2021-04-18 https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1618086246127-P7MMMZGHR598Z8E6Q1X9/BioSherpa+STSwidesmall.png The BioSherpa Solution - The BioSherpa™ Specimen Transport System (STS) Solution https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1618081509860-RBO0LWZXYJAR2VSI0SYM/BioSherpaSTS-Banner.png The BioSherpa Solution https://biosherpa.com/biosherpas-potential-value daily 0.75 2021-04-16 https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1575038979501-6VAC76BC8KXOBSTEAX57/value_added.jpg BioSherpa's Potential Value - Creates Real Infectious Disease Value-added BioSherpa™ STS can improve diagnostic specificity, financials, and Case Mix Index (CMI) while simultaneously decreasing antibiotic-related adverse events and observed/expected mortality metrics. https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1575038951361-EIUHCILMV06HAPM9CUK1/99847313_s.jpg BioSherpa's Potential Value - Improved Antibiotic Stewardship BioSherpa™ STS has the ability to improve diagnostic results, which promote the move from broad spectrum to targeted antibiotic therapy. https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1618121933189-SIVZSJ19ETFFIT8EM6N8/100334884_m.jpg BioSherpa's Potential Value - Diagnostic Accuracy By delivering reliable, accurate culture results even in antibiotic treated patients, BioSherpa™ STS facilitates a range of therapeutic interventions including sepsis protocols and other infection control mandates. https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1618122539010-QZNXNT0HVXLCJHNQQYRK/BioSherpaSTS-Banner.png BioSherpa's Potential Value https://biosherpa.com/biosherpa-origins daily 0.75 2021-04-16 https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1575036987583-WLWOV8M9WY858JKFLNXH/IMG_3664.jpg Biosherpa Origins Tom Cumbo and Destin Radder outside Patan hospital, Kathmandu, Nepal 2000 https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1574968822429-TVHUSP5II354XAYCNDUL/2000-trail+-+hra+guys.jpeg Biosherpa Origins Govinda, Rishi, Prakash, and Sanjay of the Himalayan Rescue Association assisted Cumbo and Radder on all research projects into the Nepali Himalaya. https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1575036992937-H4I9IT08PIGZ6V5A01YC/IMG_3666.jpg Biosherpa Origins Tom Cumbo and Dr. Buddha Basnyat in Patan Hospital, Kathmandu, Nepal 2000 https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1574968837705-ZS7M3YZY30D4BYXJT475/Anapurna0008.jpg Biosherpa Origins https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1574968836401-1BXW4WDZ65VYQRHL8NCU/Gosankunda004.jpg Biosherpa Origins https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1575037023522-S0EH1J9B4T3567LVO72Y/IMG_3674.jpg Biosherpa Origins Prakash, Govinda and Tom Cumbo 2000 https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1575166709727-INTRLC34Y2K4CD3OG88U/2000-fest-tom+and+govi+in+clinic+copy.jpg Biosherpa Origins https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1575037004113-ACNV511EMYZETYEYDTY8/IMG_3668.jpg Biosherpa Origins https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1574968852773-8I7DJKR0AW6U7FGJ93L1/Gosankunda011.jpg Biosherpa Origins https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1575037013742-4QD9ACSSFPGBF2X5NJ7H/IMG_3671.jpg Biosherpa Origins Destin Radder setting up research facilities, Lake Gosainkunda, Langtang district, Nepal 2000 https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1574968841917-TEHDJNHJXJXWBHJ60OA2/Gosankunda017.jpg Biosherpa Origins https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1574968865538-WC81Y5J584DA3Z1OHFET/Gosankunda036.jpg Biosherpa Origins https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1574968853300-CSRWTHL3MNGWUKJX3MDL/Gosankunda033.jpg Biosherpa Origins https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1575037026579-MAHFOP3YYTS3KG7E4DP8/IMG_3676.jpg Biosherpa Origins https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1574968861346-UG0PNUINNNYYB2OCHVAC/Mcderm-R12-32+copy.jpg Biosherpa Origins Destin Radder and Tom Cumbo recording data at the start point of the 3 day trek to Lake Gosainkunda, Dunche, Nepal 2001 https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1574968864795-NYLFYL4GFL736ZTLHWB2/teahouse-5x7-color-2copies.jpg Biosherpa Origins Radder and Cumbo in a teahouse, a place you can stay overnight and get a meal on the 3 day trek to Lake Gosainkunda, 2001 https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1575036985699-K3R8155L05RJ0W3LJB3A/IMG_3662.jpg Biosherpa Origins Cumbo and Radder in the Andes mountains, Peru 2003 https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1575036999779-5NQRV73WNLANFWVEK6ZC/IMG_3667.jpg Biosherpa Origins https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1575037008408-R015NHS5I5GOJAS7AE09/IMG_3669.jpg Biosherpa Origins Cumbo and Dr. Basnyat discussing final plans before heading to Lake Gosainkunda, 2000 https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1575037017410-3E4BL0P98F6TC3QB4Q1F/IMG_3673.jpg Biosherpa Origins https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1575037025385-J7ZZ3CS58FVLD4ZJOR82/IMG_3675.jpg Biosherpa Origins https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1575165348763-06LK9N2Z3K6OC9XS4R66/00-T-+tom+and+govi.jpg Biosherpa Origins https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1618162069768-CUQGTH814DT176JPYJUK/Kathmandu035.jpg Biosherpa Origins Cumbo and Radder in Kathmandu 1998 https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1574968979108-TBUVDBX47MB1KVYFX3KS/Mcderm-R12-32+copy.jpg Biosherpa Origins Destin and Tom, Dunche, Nepal 2001 recording data at the origin of the 3 day climb to Lake Gosainkunda https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1575037156207-0NS7HCO2CLWGFISRL1EH/IMG_3666.jpg Biosherpa Origins Thomas Cumbo and Dr. Buddha Basnyat, Patan Hospital, Kathmandu, Nepal 2000 https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1575037431295-X2D9WQ9Z06L5QCVKAAGV/IMG_3675.jpg Biosherpa Origins Cumbo attending to patient in 2000 with high altitude cerebral edema using dexamethasone. https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1575038261146-Z0HUP7NPM96K790QAPN0/IMG_3662.jpg Biosherpa Origins Radder and Cumbo in the Andes mountains of Peru, 2003. https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1574968711708-B16TT765ADX8ELYSQ4XY/Anapurna0002.jpg Biosherpa Origins https://biosherpa.com/new-page-1 daily 0.75 2019-11-29 https://biosherpa.com/founders daily 0.75 2025-03-13 https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/b50b39af-48ef-402c-a8ed-fd634892fd62/Chris-headshot-blue-wide.jpg Founders - Christopher Hutson, MD, MBA CEO Dr. Hutson started his career as an Army infantry officer and after serving several tours he pursued medical school at the Uniformed Services University of the Health Sciences where he earned his MD. He continued service in the US Army Medical Corps as an anesthesiologist for a decade in diverse geographic locations around the world. Following his military career, he entered private practice in Houston, Texas and subsequently received an MBA in Healthcare Leadership and Administration from UT Dallas. In addition to performing his duties as CEO of BioSherpa, LLC, he continues to work as a clinical anesthesiologist and physician leader to ensure that his clinical skills remain strong. Through this work, he has his finger on the pulse of the rapidly changing dynamics of healthcare. CLHutsonMD@gmail.com https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1618797149983-HFJ2XKJ7HPPPFZJ95LEF/DJ-Headshot-blue-wide.png Founders - Destin Radder CTO Radder is a CAD-certified designer and accomplished project manager. He was integral to the design and development of BioSherpa's Specimen Transport System and currently leads the company's International Research division. With a multifaceted background, Radder has excelled in diverse roles, including Key Grip and Best Electric on motion picture film sets in California, as well as Head of the Exhibits Department at the Buffalo Museum of Science. These roles enabled him to refine his skills in electrical work, mechanics, construction, and manufacturing, ensuring projects were completed efficiently and within budget. As the Director of Research Logistics in Nepal and Peru, Radder successfully navigated complex environmental and political landscapes to guarantee the seamless execution of clinical care and research initiatives. Having traveled to over 25 countries, he brings a unique ability to connect with individuals from varied cultures and backgrounds, fostering collaboration and understanding across teams. DJRadder@gmail.com LinkedIn Bio https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1618796874960-SF27KA0PL0AGS29XVA79/Tom-headshot-blue-wide.png Founders - Tom Cumbo, MD, MS, FACHE CMO After graduating from Jacobs School of Medicine in Buffalo, NY, Dr. Cumbo did his Internal Medicine Residency and Chief Residency training at The Johns Hopkins University/Sinai Hospital Program in Internal Medicine in Baltimore, MD. He continued his training in Infectious Diseases Medicine at Jacobs and then entered private practice of Infectious Diseases. In addition to his research, he pursued a Master's Degree in Healthcare Administration at UT Dallas. Along with serving as chief medical officer of BioSherpa™, LLC he continues to practice clinical infectious diseases medicine and is the former Vice President of Medical Affairs of Mount St. Mary's Hospital (a ministry of Catholic Health of Buffalo, NY). TomCumbo@protonmail.com Linkedin Bio https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1618038527852-W6VIANWASF4NH56J6BX5/BioSherpaLLC-Banner.png Founders https://biosherpa.com/streptococcus-pneumoniae-isolated-from-patient-on-several-days-of-antibiotics daily 0.75 2021-04-16 https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1618099315105-WZT1SN6T6U4QV068J7X0/032b+strep+pneumo+%26+control-i-narrow.png Streptococcus pneumoniae isolated from patient on several days of antibiotics - BioSherpa ™ STS cultured S. pneumoniae despite 2 days of antibiotics Only BioSherpa™ STS revealed S. pneumoniae as the causative pathogen whereas standard collection methods yielded only normal flora. https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1575508960799-MPDAQB17F4KX4UUOWVGT/%2332.jpeg Streptococcus pneumoniae isolated from patient on several days of antibiotics - Streptococcus pneumoniae subcultured and proven. BioSherpa™ STS was able to prove that there was still active and infectious S. pneumoniae after the patient was on antibiotics for two days. https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1618099593041-GOGMJ9TMJR8KZSVZ52Y5/032+s.+pneumoniae+close+up-i.png Streptococcus pneumoniae isolated from patient on several days of antibiotics - Streptococcus pneumoniae This patient had a positive S. pneumoniae urine antigen. This test indicates that the patient suffered from an invasive infection that wasn’t detected with standard sputum or blood cultures. Previous to the initial test, antibiotics had been started for sepsis and had killed the causative pathogen in the standard sputum culture. When BioSherpa™ STS was used, it was able to release the causative pathogen from its protective biofilm for a proper diagnosis. https://biosherpa.com/financial-case-for-biosherpa daily 0.75 2021-04-06 https://biosherpa.com/staphylococcus-aureus-haemophilus-isolated-from-patient-on-several-days-of-antibiotics daily 0.75 2021-04-16 https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1618099830900-OYOZFNGQ2S050DM3PZ9V/Haemo%26S.Aureus-i2.png Staphylococcus aureus & haemophilus isolated from patient on several days of antibiotics - BioSherpa ™ STS cultured S. aureus AND Haemophilus despite antibiotic use. BioSherpa™ STS cultured TWO different significant organisms. This result enabled a specific diagnosis and de-escalation of antibiotic therapy. Standard methods yielded only normal flora which would have required continued broad-spectrum antibiotic use. https://biosherpa.com/biosherpa-diagnosed-aspiration-pneumonia-on-antibiotics-1 daily 0.75 2021-04-16 https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1617726708831-9MQYXN5LVH6E8SZD6JS9/variant+strepwide.png BioSherpa™ STS Supports Growth of Nutritionally Variant Organism - BioSherpa ™ STS grew nutritionally variant Streptococcus while the patient was on broad spectrum antibiotics Nutritionally variant Streptococci are not typically able to be isolated using standard media and can be missed as a cause of pneumonia. In this example, Granulicatella, a pathogenic nutritionally-variant Streptococcus was easily isolated using BioSherpa™ STS (bottom) while the control sample grew none. We suspect that a component of BioSherpa™ STS provides the requisite nutrient to support growth. https://biosherpa.com/klebsiella-oxytoca-isolated-from-patient-on-several-days-of-antibiotics daily 0.75 2021-04-19 https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1618098914100-28VJ2CIOULAV1OS220WY/028+kleb+%26+control-i-narrow.png Klebsiella oxytoca isolated from patient on several days of antibiotics - BioSherpa ™STS grew Klebsiella oxytoca despite 3 DAYS of effective antibiotics This is an example of how BioSherpa™ STS can be a game changer. After 3 days of effective antibiotics the control sample showed no growth other than normal flora. BioSherpa™ STS can enable doctors to obtain a specific diagnosis and de-escalate antibiotic therapy. In fact, our research shows that if BioSherpa™ STS is used, there is at least a 30% greater chance of isolating the causative pathogen when a patient is on antibiotics compared to standard methods. https://biosherpa.com/staph-aureus-isolated-from-bone-sample-of-patient-on-antibiotics-and-after-sample-was-frozen daily 0.75 2021-04-16 https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1575771370043-CILQZ2ML2W9ADKW2GEXO/021+control.png Staph aureus isolated from bone sample of patient on antibiotics and after sample was frozen - The control sample yielded inferior results. All dishes to the left show the sample collected using standard collection methods. The control showed inferior growth and did not grow the S. aureus. https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1618100292556-SRL3BK7NCXX8CT66X8FF/021+Biosherpa+s+aureus+frozen-i.png Staph aureus isolated from bone sample of patient on antibiotics and after sample was frozen - BioSherpa ™ STS has the ability to grow a causative pathogen even after being frozen. BioSherpa™ STS (all dishes pictured to the left) was able to grow S. aureus despite the use of antibiotics AND being frozen. In addition much heavier growth can be seen compared to control (below). https://biosherpa.com/biosherpa-sts-facilitates-growth-of-organism-more-rapidly-than-conventional-methods daily 0.75 2021-04-16 https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1618113361795-PICKIQHXMDPNHM13WW2J/proteus+48hours-i.png BioSherpa™ STS facilitates growth of organism more rapidly than conventional methods - The control did not reveal Proteus until 48 hours after plated. The BioSherpa™ STS plate is covered with Proteus to the point that it no longer looks like a blood plate. The control plate is just starting to show growth of Proteus at 48 hours. https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1618101387662-NOCYNYBIMRQZ2TOAMMYG/067+Proteus+24hours-i-narrow.png BioSherpa™ STS facilitates growth of organism more rapidly than conventional methods - The use of BioSherpa™ STS facilitated the identification of Proteus 24 hours earlier than control, which allowed for clinical modification of the patient’s care. BioSherpa™ STS facilitates faster diagnosis of infectious agents. This photo illustrates 24 hours of growth. The “swarming” characteristic of the Proteus is evident on the BioSherpa™ STS plate. It is easily distinguishable from the Pseudomonas also growing on both plates. There is no clear growth of Proteus on the control plate. The isolation of Proteus a full 24 hours earlier allowed us to modify antibiotic therapy sooner than would otherwise be possible. Pseudomonas is present on both control and BioSherpa™ STS at 24 hours. The Proteus is easily distinguishable from the Pseudomonas on BioSherpa™ STS but not on control. https://biosherpa.com/biosherpa-sts-competitive-advantages daily 0.75 2021-04-09 https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1617989569783-W4BU1IXRC8TUHZQR39R2/Competative%2Badvantages.jpg BioSherpa STS Competitive Advantages https://biosherpa.com/multiple-pathogens-isolated-from-bone-sample-patient-on-broad-spectrum-antibiotics daily 0.75 2021-04-16 https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1618101050126-MJBZQWOBQGPETAGGBNYH/026+bone+blood+plate-i.png Multiple pathogens isolated from bone sample while patient on broad-spectrum antibiotics - BioSherpa ™ STS identified multiple strains from a bone sample while a patient was on antibiotics. BioSherpa™ STS can be used for a variety of biological samples. In this example we see how it can be used to coax causative pathogens out of a bone sample. This is extremely significant because the patient was on vancomycin and piperacillin tazobactam for 6 days before culture. This infection also had an aggressive soft tissue component and required immediate broad spectrum treatment before eventual bone culture (from amputation). https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1618101177670-MEUIPFMHCPZYLM1PR2HI/026+choco+bone+plate-i.png Multiple pathogens isolated from bone sample while patient on broad-spectrum antibiotics - BioSherpa ™ STS yielded multiple strains whereas controls yielded none. BioSherpa™ STS could potentially help elucidate the infectious agent in samples that traditionally yield negative results. This patient required more aggressive antibiotic therapy. Reliance on standard bone culture techniques would have left the patient under-treated and at high risk for failure. https://biosherpa.com/staphylococcus-aureus-isolated-from-bone-after-weeks-of-antibiotic-resolved-inflammatory-markers daily 0.75 2021-04-16 https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1618114014674-6GWP258C15KTMDGF4KG6/Surgical+bone+culture.png Staphylococcus aureus isolated from bone after weeks of antibiotic & resolved inflammatory markers - Surgical bone culture after weeks of effective antibiotics and normalization of inflammatory markers The culture result on the left was the original isolate at the time of diagnosis. The culture result on the right was taken after weeks of antibiotic therapy and normalization of inflammatory markers. The same isolate was present based on the antibiotic susceptibility pattern. These results show that the organism was contained in a biofilm in the native bone and was coaxed out using BioSherpa™ STS. They also show that the antibiotic therapy failed and that further therapy and debridement was necessary. This information would not have been revealed using standard culture techniques. Control had no growth. https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1618113590208-GISCXJXTAHKPQP6M24R6/S.aureus+from+bone.png Staphylococcus aureus isolated from bone after weeks of antibiotic & resolved inflammatory markers - S. aureus was isolated from bone after weeks of antibiotic therapy using BioSherpa™ STS. BioSherpa™ STS facilitated the detection of S. aureus persister cells in the infected bone sample, indicating incomplete treatment of the infection. https://biosherpa.com/staphylococcus-aureus-isolated-from-bone-after-weeks-of-antibiotic-resolved-inflammatory-markers-1 daily 0.75 2021-04-16 https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1618114673165-RHMRND3XWY7E2N6C4HQI/H.Pylori-square.png Helicobacter pylori isolated with BioSherpa STS without stringent transport and handling - Helicobacter pylori was isolated from a gastric sample using BioSherpa™ STS. This organism is notoriously difficult to isolate in culture and requires stringent transport conditions. BioSherpa™ STS facilitates the culture of this organism without complex and expensive transport and handling. H. pylori is being treated empirically because of the complexities of collection and culture despite a 20-30% antibiotic resistance rate. BioSherpa™ STS supports uncomplicated culture, transport and handling from endoscopic samples, allowing for antibiotic susceptibility testing and better care. https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1618114915250-QCD6TD594W1Y2VORYISZ/H.pylori-closeup.png Helicobacter pylori isolated with BioSherpa STS without stringent transport and handling https://biosherpa.com/home-new daily 0.75 2021-04-10 https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1618035499920-VS6SBBO29AN6ZLAWEL6V/Founders.png Home (New) - Founders Corporate Team Origins of BioSherpa™ https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1618007432967-I71FM0GLK1TIXTGNKGLO/money-series-3-1238159-1278x855.jpg Home (New) - BioSherpa™ STS can increase potential revenue by providing accurate culture results. Accurate results lead to the use of specific codes which result in higher reimbursement rates and to the streamlining of antibiotic therapy which typically will reduce the cost to hospitals. Learn more about how BioSherpa STS can increase potential revenue… https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1618035329883-VQ33QCV3ZC0FEHMW4EIA/The+Problem-lower.png Home (New) - Standard Collection of Biological Samples If a sample taken from a patient is not immediately cultured on the petri dish, the infectious organisms can die before the sample reaches the lab. As a result causative pathogens can easily be missed. Learn more about the problem with conventional sample collection… https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1618030608220-E7O68C1LI2LL9FDPF99U/BioSherpa+short+vid+pic+copy.png Home (New) - Watch BioSherpa™ STS in action. Watch Here https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1618035435204-79FII6SSJO08FTN4UUIU/The+Solution+no.png Home (New) - BioSherpa™ Specimen Transport System (STS) BioSherpa™ STS dramatically increases the chance that a culture will identify a causative pathogen, even when the patient is on antibiotics that traditionally sterilize the sample. Learn more about BioSherpa™ STS… https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1575038979501-6VAC76BC8KXOBSTEAX57/value_added.jpg Home (New) - BioSherpa™ STS value proposition is threefold: Supports Sepsis Protocols by delivering reliable, accurate culture results even in antibiotic treated patients. Learn more about BioSherpa™ STS’s value proposition… https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1618037859257-XJNGY5D9ACDYE8VAWIUW/028+kleb+%26+control-wide.png Home (New) - BioSherpa™ STS is a game changer. Through the use of BioSherpa™ STS, we can isolate pathogens that typically die or hide in the mass of commensal organisms. Learn more about BioSherpa STS’s examples of superior microbiological results. https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1618004201555-VPIMAGK3ENEEVEDFVTUA/BioSherpa+STSwidesmall.png Home (New) - BioSherpa™ Specimen Transport System (STS) https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1618036240447-8NKS2JR88HA9MWU37NZL/Competative+advantages2.png Home (New) - Competitive Advantages https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1618029800919-Y6DASSQUZA839JLKICMZ/Biosherpa+LLC+banner.png Home (New) https://biosherpa.com/biosherpa-soution-1 daily 0.75 2021-04-09 https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1617659585541-ZFX205R1AJKWT1ZOCOSY/028+kleb+%26+control.png BioSherpa Solution (Copy) - BioSherpa™ STS is a game changer. Through the use of BioSherpa, we can isolate pathogens that typically die or hide in the mass of commensal organisms. Here we see small numbers of alpha strep that may be Pneumococcus hidden in a community of Staph species. The control sample only grew the single Staph variant. https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1617986834686-5CTL8KACC00W7RQK2MQU/BioSherpa+STSwide2.png BioSherpa Solution (Copy) - BioSherpa™ Specimen Transport System BioSherpa™ STS is a unique combination that disrupts an organism’s biofilm protective matrix, encouraging bacteria to grow and be evaluated in its planktonic state. https://biosherpa.com/financial-case-for-biosherpa-1 daily 0.75 2021-04-09 https://biosherpa.com/the-problem daily 0.75 2021-04-11 https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1618089391642-3PMFXS1UMVBIIYO23QGR/BioSherpaSTS-Banner.png The Problem https://biosherpa.com/examples-of-superior-microbiological-results daily 0.75 2021-04-19 https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1618093878947-QBCC72F84E4HG49L39S9/032b+strep+pneumo+%26+control-i.png Examples of Superior Microbiological Results - BioSherpa™ STS isolated Streptococcus pneumoniae from a patient on several days of antibiotics. Only BioSherpa™ STS revealed S. pneumoniae as the causative pathogen whereas standard collection methods yielded only normal flora. Learn More… https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1618095050314-J0IDEOJPFFXXYLLPK41C/026+choco+bone+plate-i.png Examples of Superior Microbiological Results - BioSherpa ™ STS identified multiple strains from a bone sample while the patient was on antibiotics. Learn More… https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1618026757982-F10TQ3JZSNZV11M5PPJX/Nut+variant+strep.png Examples of Superior Microbiological Results - BioSherpa ™ STS grew nutritionally variant Streptococcus while a patient was on broad spectrum antibiotics. Learn More… https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1618099136162-TREJ2HFG336ZVGUYUA6H/028+kleb+%26+control-i.png Examples of Superior Microbiological Results - BioSherpa™ STS isolated Klebsiella pneumonia despite 3 days of effective antibiotics. BioSherpa™ STS isolated Klebsiella pneumonia despite 3 days of effective antibiotics. Learn More… https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1618100161329-PQPODYEEGB7OSRNQ0QEC/021+Biosherpa+s+aureus+frozen-i.png Examples of Superior Microbiological Results - BioSherpa ™ STS has the ability to grow a causative pathogen even after being frozen. Learn More… https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1618098248879-HO6TYAW90SY1D1V328YT/067+Proteus+24hours-i.png Examples of Superior Microbiological Results - BioSherpa™ STS identified Proteus 24 hours earlier than control, and allowed for clinical modification of the patient’s care. Learn More… https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1618027458165-6XERRBMSDKIJIL6M914M/H.Pylori.png Examples of Superior Microbiological Results - BioSherpa™ STS isolated Helicobacter pylori from a gastric sample. Learn More… https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1618094163243-7U0Z3ZQZZBPWH5YV73H1/Haemo%26S.Aureus-i.png Examples of Superior Microbiological Results - BioSherpa ™ STS cultured Staphylococcus aureus AND Haemophilus spp. despite antibiotic use. BioSherpa™ STS grew out TWO different significant organisms. This enabled a specific diagnosis and de-escalation of antibiotic therapy. Learn More… https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1618027201361-NZ811RJL10CN50EE3SWW/Staph+Aureaus.png Examples of Superior Microbiological Results - BioSherpa™ STS isolated S. aureus from bone after weeks of antibiotic therapy. Learn More… https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1618034494126-HAX7EMJP9BY038R6L4OH/BioSherpaSTS-Banner.png Examples of Superior Microbiological Results https://biosherpa.com/watch-biosherpa-in-action daily 0.75 2021-04-10 https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1618031389954-IOBRT8Q7N242GGQR5BAP/BioSherpaSTS-Banner.png Watch BioSherpa in action https://biosherpa.com/case-study daily 0.75 2021-04-16 https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1618121249736-TJPBWAWQC0WM2JZW0WFA/028+kleb+%26+control-i-narrow.png Case Study - BioSherpa™ STS provided a more accurate diagnosis that resulted in: A de-escalation of antibiotic treatment to the patient, avoiding significant side effects and cost. An increase in hospital Case Mix Index due to diagnostic specificity. An economic benefit to the hospital of almost $1,800 resulting from a cost savings of almost $1,000 by using a more targeted antibiotic and an increased reimbursement to the hospital of almost $800 due to allowances for enhanced diagnostic specificity. More accurate data that will easily interface with advanced electronic medical record charge capture platforms such as Epic. https://images.squarespace-cdn.com/content/v1/5b76d2b1ee1759d0a09ae6cc/1618087330986-I2DMN08YZ6GNUGW7K4C6/BioSherpaSTS-Banner.png Case Study